Visit for the latest Coronavirus Disease (COVID-19) updates.

You are here

Evidence-Based Resource Summary

Strength of Evidence: 
4 out of 4
4 out of 4
Year Published: 

Celecoxib for Rheumatoid Arthritis

Description of Resource: 
This Cochrane systematic review assesses the benefits and harms of celecoxib, a selective non-steroidal anti-inflammatory drug (NSAID), in people with rheumatoid arthritis. This systematic review included 8 randomized control trials with durations of 4 to 24 weeks, published between 1998 and 2014, that involved a total of 3,988 adults (mean age = 54 years), most of whom were women (73%), and found that celecoxib may improve clinical symptoms, alleviate pain, and contribute to little or no difference in physical function compared with placebo.

Evidence-Based Resource Details

help Learn more about EBR criteria
Developed By: 
Cochrane Library
Developer Type: 
Non-Federal Government
Healthy People 2020 Topic Area(s): 
Arthritis, Osteoporosis, and Chronic Back Conditions
Healthy People 2020 Objectives: 
Resource Type: 
Systematic Review
Fidahic M, Jelicic Kadic A, Radic M, Puljak L. Celecoxib for rheumatoid arthritis. Cochrane Database of Systematic Reviews 2017, Issue 6. Art. No.: CD012095. doi: 10.1002/14651858.CD012095.pub2. Available from: